ImmunoGen Q2 Profit Results Beat View; Backs 2015 Outlook - Quick Facts

(RTTNews) - ImmunoGen, Inc. (IMGN), a developer of targeted anticancer therapeutics, reported net income for the second quarter of $13.64 million or $0.16 per share, up from $3.81 million or $0.04 per share in the year-ago period.

On average, fifteen analysts polled by Thomson Reuters expected the company to report loss of $0.05 per share for the quarter. Analysts' estimates typically exclude special items.

Revenues for the quarter grew to $48.30 million from $30.06 million in the year-ago period. Analysts had a consensus revenue estimate of $37.08 million.

Looking ahead, ImmunoGen affirmed its fiscal 2015 outlook for revenues between $100 million and $105 million and net loss between $60 million and $65 million. Analysts expect the company to report loss of $0.70 per share for the year on revenues of $99.42 million.